Crossmark

Serum CA125 is independently associated with adverse outcomes in primary Sjögren’s syndrome-associated interstitial lung disease: a prospective multicenter cohort study

Crossref DOI link: https://doi.org/10.1186/s12931-026-03573-x

Published Online: 2026-02-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Meng, Wenyan

Geng, Jing

Chen, Xueying

Dai, Huaping
Funding

Funding for this research was provided by:

National Key Technologies R&D Program of China (No. 2021YFC2500700)

National High Level Hospital Clinical Research Funding (No. 2022- NHLHCRF-LX-01-0104)
License Information

Text and Data Mining valid from 2026-02-12

Version of Record valid from 2026-03-27
More Information

Article History

Received: 13 August 2025

Accepted: 6 February 2026

First Online: 12 February 2026

Declarations

:

: The study was approved by Institutional Ethics Committee of Beijing Chaoyang Hospital (ethics approval number 2019-123-K85-1) and China-Japan Friendship Hospital, Beijing, China (ethics approval number 2017-25-1). Written informed consent was obtained from all patients.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below